ArticleAntimicrobial agents and chemotherapy2011
In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Current status of drug therapy for alveolar echinococcosis.World journal of hepatology · 2024Review
- Chemotherapy for the treatment of alveolar echinococcosis: Where are we?Parasite (Paris, France) · 2024Review
- Investigation of the mechanism of action of mefloquine and derivatives against the parasite Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2023Article
- Salvage Therapy for Alveolar Echinococcosis-A Case Series.Pathogens (Basel, Switzerland) · 2022Article
- Therapeutic Efficacy of Albendazole and Mefloquine Alone or in Combination Against Early and Late Stages ofHelminthologia · 2021Article
- Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2020Article
- Article
- Glycogen Phosphorylase: A Drug Target of Amino Alcohols inFrontiers in microbiology · 2020Article
- The importance of being parasiticidal… an update on drug development for the treatment of alveolar echinococcosis.Food and waterborne parasitology · 2019Article
- Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2018Article
- Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2018Article
- Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.PLoS neglected tropical diseases · 2018Article
- Article
- A Rapid and Convenient Method for in Vivo Fluorescent Imaging of Protoscolices of Echinococcus multilocularis.The Korean journal of parasitology · 2016Article
- Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis.PLoS neglected tropical diseases · 2016Article
- Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse model.Veterinary research · 2016Article
- In vivo and in vitro efficacies of mebendazole, mefloquine and nitazoxanide against cyst echinococcosis.Parasitology research · 2015Article
- Efficacy of Albendazole-Chitosan Microsphere-based Treatment for Alveolar Echinococcosis in Mice.PLoS neglected tropical diseases · 2015Article
- Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.PLoS neglected tropical diseases · 2014Article
- Repurposing drugs for the treatment and control of helminth infections.International journal for parasitology. Drugs and drug resistance · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alveolar echinococcosis (AE) is caused by the metacestode stage of the fox tapeworm Echinococcus multilocularis and causes severe disease in the human liver, and occasionally in other organs, that is fatal when treatment is unsuccessful. The present chemotherapy against AE is based on mebendazole and albendazole. Albendazole treatment has been found to be ineffective in some instances, is parasitostatic rather than parasiticidal, and usually involves the lifelong uptake of large doses of drugs. Thus, new treatment options are urgently needed. In this study we investigated the in vitro and in vivo efficacy of mefloquine against E. multilocularis metacestodes. Treatment using mefloquine (20 μM) against in vitro cultures of metacestodes resulted in rapid and complete detachment of large parts of the germinal layer from the inner surface of the laminated layer within a few hours. The in vitro activity of mefloquine was dependent on the dosage. In vitro culture of metacestodes in the presence of 24 μM mefloquine for a period of 10 days was parasiticidal, as determined by murine bioassays, while treatment with 12 μM was not. Oral application of mefloquine (25 mg/kg of body weight administered twice a week for a period of 8 weeks) in E. multilocularis-infected mice was ineffective in achieving any reduction of parasite weight, whereas treatment with albendazole (200 mg/kg/day) was highly effective. However, when the same mefloquine dosage was applied intraperitoneally, the reduction in parasite weight was similar to the reduction seen with oral albendazole application. Combined application of both drugs did not increase the treatment efficacy. In conclusion, mefloquine represents an interesting drug candidate for the treatment of AE, and these results should be followed up in appropriate in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.